By PPN News Staff
When added to standard therapies, dupilumab (Dupixent, Sanofi/Regeneron) reduced severe asthma exacerbations and improved lung function, according to a phase 3 study in a broad population of patients with uncontrolled, persistent asthma.
In March, the FDA approved dupilumab for the treatment of moderate to severe atopic dermatitis (AD) that is not adequately controlled with topical prescription therapies, but it is not indicated for asthma. Dupilumab is the first and only